Key Takeaway: Annexon has reported positive clinical outcomes from the GBS FORWARD study, reinforcing the effectiveness of Tanruprubart. The treatment's consistency and reproducibility were highlighted, with a Biologics License Application (BLA) submission anticipated in Q4 2026. Additionally, the Phase 3 GA program for Vonaprument has been expanded, focusing on dual primary endpoints at months 15 and 24.
Market Sentiment Analysis
POSITIVE FACTORS
Rapid, positive clinical outcomes reported in the GBS FORWARD study.
Consistency and reproducibility of Tanruprubart treatment effect confirmed.
BLA submission expected in Q4 2026, indicating progress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+28%
120-day peak, hindsight
Typical move
3.8%
average across 9 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
ANX005
Phase 3 · Guillain-Barre Syndrome
Full Press Release Details
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026 Vonaprument Phase 3 GA Program Expanded with Month 15 / 24 Dual Primary
Frequently Asked Questions
What were the clinical outcomes in the GBS FORWARD study?
The GBS FORWARD study reported rapid and positive clinical outcomes.
When is the BLA submission expected?
The Biologics License Application (BLA) submission is expected in Q4 2026.
What does the Phase 3 GA program for Vonaprument involve?
The Phase 3 GA program for Vonaprument has been expanded to include dual primary endpoints at months 15 and 24.